Table 6. Results of Studies Combining Chemoradiotherapy with Immunotherapy in Stage III NSCLC.

	n	Intervention	DFS	OS (%)	Toxicity>Grade 3 (%)
PACIFIC [6,117]	714	CRT (54–66 Gy)→Durvalumab.	Median, 18.8 months	1 year: 83.1 2 year: 66.3	30.5
LUN 14-179 [119]	92	CRT (59.4–66 Gy)→Pembrolizumab.	Median, 15.4 months	1 year: 80.5 2 year: 68.7	6.5
ETOP NICOLAS [121,125]	80	CRT (66 Gy)+Nivolumab→Nivolumab 1 year	1 year: 54%	1 year: 79	10.9
DETERRED [120]	40	Part 1: CRT (60–66 Gy)→CT+Atezolizumab×2 cycles→Atezolizumab 1 year Part 2: CRT (60–66 Gy)+Atezolizumab→CT+Atezolizumab×2 cycles→Atezolizumab 1 year	1 year: 57%	1 year: 79	27.5

DFS: Disease-free survival, OS: Overall survival, CRT: Chemoradiotherapy, CT: Chemotherapy